Navigation Links
As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
Date:1/4/2012

SYDNEY, Jan. 4, 2012 /PRNewswire/ -- The Company today announced that it has modified the provisions of its American Depository Receipt ("ADR") program.  The previous conversion ratio of 5 Novogen Limited ordinary shares for each ADR share will now be 25 Novogen Limited ordinary shares for each ADR share.  The change will be effective from 3 January, 2012.  The change in the ADR ratio will have no effect on the number of outstanding common shares the company has on issue or the listing of its common shares on the ASX.

In making the announcement, William D Rueckert, Chairman stated: "The ratio change and resulting increase in the market price for our ADR shares, as listed on NASDAQ, will bring our ADR shares back into compliance with NASDAQ's $1.00 minimum bid price requirement. We believe that continued listing on both the ASX and NASDAQ provides important liquidity on two major exchanges for our shareholders and for the Company."

In a separate transaction, the Company also announced today that it has made an additional investment in its majority owned drug development subsidiary, Marshall Edwards with the purchase 1,941,747 common shares for a total of $2,000,000. The proceeds will support the continued development of Marshall Edward's drug development programs.

About Novogen Limited

Novogen Limited (ASX: NRT, Nasdaq: NVGN, Nasdaq: NVGND) is an Australian biotechnology company based in Sydney, Australia.  Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc.  More information on the Novogen group of companies can be found at www.novogen.com.


'/>"/>
SOURCE Novogen Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
2. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
3. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
4. New cow genome sequence released
5. GeneCards(R) Version 3.0 Beta Released
6. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
7. Prescription-Free Digital Hearing Aid Just Released
8. Jatropha Couple Oil Crop Cultivation Technology Commercially Released
9. Sevocity EHR 08 Released With ARRA (Stimulus) Commitment
10. The 2010 Bio-IT World Best Practices Call for Entries has been Released -- Highlight your Company's Excellence in Innovation
11. Novel Imaging Software Released by Celsense Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2020)... ... February 04, 2020 , ... Shoreline Biome , ... the strain level, has announced a new distribution partnership in Asia. , The ... products to companies and research organizations in China, Hong Kong, and Macau. , ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... announced the release of Genedata Expressionist ® 13.5 at the 2020 ... Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during ... millions of people around the world. And as Slone Partners celebrates ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... with the precision of Genome editing. The partners have agreed to co-develop and ... of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term, the parties aim ...
Breaking Biology Technology:
(Date:1/24/2020)... LOS ANGELES (PRWEB) , ... January 24, 2020 , ... ... Rapid Release Technology President Dr. Stanley Stanbridge and Vice President of Sales and ... air on Fox Business Network as sponsored content on Sunday, Jan. 26, 2020 at ...
(Date:1/22/2020)... , ... January 21, 2020 , ... ... to lead the company’s new Business Development Department. The move, which is part ... had been previously serving as the company’s Senior Vice President where he oversaw ...
(Date:1/8/2020)... ... January 08, 2020 , ... R3 Stem Cell, ... to its nationwide practice network partners. Not only does this save practices ... its Network the biologics themselves are less expensive. , Since the regenerative biologics ...
Breaking Biology News(10 mins):